| 1460 |
National Cancer Institute |
Html |
en |
Adjustment to Cancer: Anxiety and Distress (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the difficult emotional responses many cancer patients experience. This summary focuses on normal adjustment issues, psychosocial distress, and adjustment disorders. |
| cancer treatment | 0.348496 |
| adjustment disorders | 0.377426 |
| newly diagnosed cancer | 0.338474 |
| palliative care specialist | 0.336033 |
| emotional distress | 0.481089 |
| recurrent breast cancer | 0.355658 |
| ambulatory cancer patients | 0.342576 |
| psychological distress | 0.361971 |
| Japanese cancer patients | 0.3428 |
| Cancer Network Distress | 0.42624 |
| early-stage breast cancer | 0.450601 |
| adult cancer patients | 0.342011 |
| posttreatment distress | 0.33562 |
| health care professionals | 0.348864 |
| normal adjustment | 0.438186 |
| adolescent cancer patients | 0.355821 |
| social support | 0.338806 |
| breast cancer patients | 0.4182 |
| patients | 0.62456 |
| cancer patients | 0.6025 |
| normal adjustment issues | 0.349617 |
| cancer diagnosis | 0.33963 |
| breast cancer survivors | 0.37097 |
| mental disorders | 0.352228 |
| psychosocial distress | 0.487249 |
|
| adjustment | 0.494267 |
| women | 0.328737 |
| distress | 0.685449 |
| psychosocial assessment | 0.364194 |
| study | 0.349859 |
| distress scores | 0.331169 |
| stage breast cancer | 0.326706 |
| breast cancer diagnosis | 0.330404 |
| palliative care | 0.44264 |
| cancer-related life events | 0.334421 |
| life | 0.404419 |
| posttreatment cancer-related distress | 0.396788 |
| general distress indices | 0.342126 |
| primary oncology team | 0.360914 |
| diagnostic criteria | 0.346926 |
| psychosocial assessment interview | 0.338281 |
| Community Cancer Care | 0.328482 |
| advanced cancer | 0.337588 |
| breast cancer | 0.994793 |
| mental disorder | 0.347463 |
| psychological well-being | 0.349655 |
| Psychosocial Distress section | 0.403402 |
| general distress | 0.349587 |
| major depressive disorder | 0.329474 |
|
CLICK HERE |
| 1590 |
National Cancer Institute |
Html |
en |
Adjustment to Cancer: Anxiety and Distress (PDQ®)–Patient Version |
Expert-reviewed information summary about the difficult emotional responses many cancer patients experience. This summary focuses on normal adjustment issues, psychosocial distress, and adjustment disorders. |
| cancer treatment | 0.390955 |
| mental health | 0.376414 |
| emotional distress | 0.342467 |
| mild anxiety | 0.297125 |
| Anxiety disorder—A condition | 0.322854 |
| long-term cancer survivors | 0.290225 |
| following PDQ summaries | 0.289376 |
| PDQ cancer information | 0.401693 |
| clinical trial search | 0.290488 |
| clinical trials | 0.374063 |
| cancer information summary | 0.360243 |
| normal adjustment | 0.315173 |
| Cancer education sessions | 0.292812 |
| patients | 0.858745 |
| cancer diagnosis | 0.420677 |
| mental health problem | 0.344798 |
| symptoms | 0.369957 |
| anxiety | 0.674027 |
| NCI PDQ cancer | 0.318604 |
| cancer survivors | 0.307582 |
| anxiety disorder | 0.421462 |
| great anxiety | 0.289049 |
| problems | 0.310639 |
| distress | 0.498316 |
| treatment | 0.584321 |
|
| cancer prevention | 0.287279 |
| NCI-supported cancer | 0.289072 |
| palliative care | 0.307485 |
| Cancer Information Service | 0.302564 |
| life | 0.319995 |
| generalized anxiety disorder | 0.307665 |
| cancer patients | 0.396085 |
| National Cancer Institute | 0.357347 |
| Cancer Care | 0.313891 |
| adjustment disorder | 0.323889 |
| Palliative Care Editorial | 0.287821 |
| Cancer Care page | 0.291913 |
| Care Editorial Board | 0.290774 |
| anxiety disorders | 0.412812 |
| stressful event | 0.352734 |
| fast heart beat | 0.32985 |
| PDQ summary | 0.441306 |
| intense anxiety | 0.302865 |
| cancer clinical trials | 0.331141 |
| cancer information summaries | 0.300508 |
| comprehensive cancer information | 0.300154 |
| cancer | 0.962959 |
| information | 0.418397 |
| depression | 0.295223 |
|
CLICK HERE |
| 1938 |
National Cancer Institute |
Html |
es |
Grados de comprobación científica de los estudios sobre el tratamiento del cáncer en adultos y niños (PDQ®)–Versión para profesionales de salud |
Información sobre cómo evaluar la solidez de los datos probatorios que se obtienen de diferentes clases de estudios sobre el tratamiento del cáncer. |
| Visuals Online | 0.667636 |
| Physician Data Query | 0.729238 |
| Benhaddad A | 0.68991 |
| oro —el ensayo | 0.814208 |
| estadÃstico kappa | 0.695883 |
| valoración indirectos | 0.767699 |
| hipótesis prospectivas explÃcitas | 0.790489 |
| amputación vs | 0.700012 |
| único diseño | 0.677496 |
| marcadores indirectos | 0.945889 |
|
| National Cancer Institute | 0.71653 |
| alto efectos | 0.677847 |
| subsequent large randomized | 0.778241 |
| controlled trials | 0.698624 |
| Grégoire G | 0.694845 |
| siguientes riesgos | 0.670189 |
| valores lÃmite | 0.703358 |
| Instituto Nacional | 0.973244 |
| historia clÃnica | 0.690891 |
|
CLICK HERE |
| 1942 |
National Cancer Institute |
Html |
es |
Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocítica crónica o juvenil y la LMC atípica. |
| French-American-British Cooperative Leukaemia | 0.312371 |
| leucemia mieloide | 0.341853 |
| myelomonocytic leukaemia | 0.397359 |
| myelomonocytic leukemia with | 0.326213 |
| platelet-derived growth factor | 0.354049 |
| with juvenile chronic | 0.315892 |
| Arber DA | 0.312178 |
| health organization classification | 0.3281 |
| Leukemia Group | 0.315441 |
| genes platelet-derived growth | 0.312347 |
| with juvenile | 0.340061 |
| chronic myeloid leukemia | 0.336615 |
| myelomonocytic leukemia | 0.944712 |
| leucemia mielomonocÃtica | 0.387953 |
| chronic myelomonocytic leukemia | 0.819447 |
| differentiating myelomonocytic leukemia | 0.320578 |
| Beran M | 0.312167 |
| World Health Organization | 0.355665 |
| neoplasias mielodisplásicas | 0.314258 |
| stem cell transplantation | 0.313202 |
| chronic myelogenous leukemia | 0.364294 |
| Germing U | 0.362762 |
| myeloproliferative disorders | 0.313394 |
| cases with chronic | 0.311538 |
| Leuk Lymphoma | 0.332534 |
|
| myelomonocytic leukemia from | 0.33992 |
| chronic myelomonocytic leukaemia | 0.386185 |
| juvenile chronic myelogenous | 0.347073 |
| marrow transplantation | 0.341155 |
| Organización Mundial | 0.317633 |
| chronic myeloid | 0.357031 |
| Differentiating juvenile myelomonocytic | 0.319715 |
| myeloid neoplasms | 0.336696 |
| bone marrow transplantation | 0.325127 |
| Bennett JM | 0.319603 |
| cromosoma filadelfia | 0.337822 |
| recuento plaquetario | 0.325577 |
| juvenile myelomonocytic leukaemia | 0.339361 |
| juvenile myelomonocytic leukemia | 0.545157 |
| chronic myeloid leukaemias | 0.320258 |
| Clin Oncol | 0.32115 |
| Orazi A | 0.343564 |
| Cooperative Leukaemia Group | 0.311788 |
| atypical chronic | 0.319445 |
| caracterÃsticas clÃnicas | 0.316309 |
| trastornos mieloides | 0.311632 |
| leucemia mieloide aguda | 0.316238 |
| with chronic myelomonocytic | 0.340508 |
| Emanuel PD | 0.350668 |
|
CLICK HERE |
| 1946 |
National Cancer Institute |
Html |
es |
Tratamiento del neuroblastoma (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del neuroblastoma. |
| glándula tiroides | 0.633074 |
| posibles efectos tardÃos | 0.641796 |
| siguientes procedimientos | 0.632822 |
| células madre | 0.931788 |
| gen alk | 0.612181 |
| siguientes especialistas | 0.624871 |
| yodo 131-mibg | 0.744725 |
| vÃa oral | 0.649411 |
| rayos x | 0.630232 |
| enlace drugs approved | 0.631928 |
| estadios 2A | 0.624814 |
| niño ayuda | 0.632627 |
| ondas sonoras | 0.629873 |
| riesgo intermedio | 0.674697 |
| efectos tardÃos | 0.896983 |
| cáncer.ampliar aspiración | 0.633221 |
|
| National Cancer Institute | 0.612675 |
| IRMN).Ampliar Imágenes | 0.62564 |
| siguientes tratamientos | 0.624353 |
| menor producción | 0.628805 |
| Instituto Nacional | 0.623964 |
| PDQ Tratamiento | 0.634123 |
| determinados cambios | 0.611022 |
| alta potencia | 0.625499 |
| presente sección | 0.614217 |
| nuevos tipos | 0.61878 |
| sistema nervioso central | 0.655496 |
| Physician Data Query | 0.650241 |
| siguientes pruebas | 0.680017 |
| siguientes estadios | 0.629707 |
| siguientes trastornos | 0.624626 |
|
CLICK HERE |
| 2064 |
National Cancer Institute |
Html |
es |
Exposición al asbesto y el riesgo de cáncer |
Hoja informativa sobre el asbesto, sobre las enfermedades relacionadas con el asbesto e incluye organizaciones para obtener más información. |
| técnicos profesionales automotrices | 0.5421 |
| gen bap1 | 0.530949 |
| que familiares de trabajadores | 0.533144 |
| normas descritas | 0.532666 |
| largo plazo | 0.526581 |
| Protección Ambiental | 0.672505 |
| World Trade Center | 0.546459 |
| principal dependencia | 0.532045 |
| Ground Zero | 0.529197 |
| derrames pleurales benignos | 0.558277 |
| Salud Ocupacional | 0.584399 |
| asbesto crisótilo | 0.987156 |
| trabajadores portuarios | 0.606054 |
| Instituto Nacional | 0.563708 |
| menores riesgos | 0.533274 |
| Trabajo de EE | 0.535904 |
| Employment Standards Administration | 0.548898 |
| titulado current best practices | 0.543841 |
| Mine Safety | 0.535362 |
| sustancias tóxicas | 0.635631 |
| siglo xix | 0.53032 |
| distintos tipos | 0.525229 |
| Estados Unidos | 0.992615 |
| automotriz usa | 0.531695 |
| Public Affairs | 0.529764 |
|
| serios problemas | 0.529441 |
| Environmental Protection Agency | 0.815767 |
| lÃnea telefónica tsca | 0.556811 |
| Preventing Asbestos Exposure | 0.544747 |
| Product Safety Commission | 0.67091 |
| Information Division | 0.52746 |
| Occupational Safety | 0.586355 |
| asbesto causa | 0.952053 |
| cuánto tiempo | 0.527545 |
| en la mucosidad | 0.531534 |
| a las personas | 0.529484 |
| posibles peligros | 0.5266 |
| Health Administration | 0.652906 |
| Consumer Product Safety | 0.672282 |
| causa dificultad | 0.530297 |
| sumamente bajo. Los fabricantes | 0.528798 |
| mejores prácticas | 0.574094 |
| Clutch Repair Workers | 0.544379 |
| Veterans Affairs | 0.528386 |
| Torres Gemelas | 0.52642 |
| Compensation Programs | 0.5287 |
| Disease Registry | 0.526245 |
| Toxic Substances | 0.526971 |
| Segunda Guerra Mundial | 0.550565 |
|
CLICK HERE |
| 2988 |
National Cancer Institute |
Html |
en |
Secondhand Smoke |
Smoking affects both you and your loved one's health. Learn about the consequences of secondhand smoke and how you can protect your family. |
| feet | 0.409991 |
| dangers | 0.420271 |
| Lung cancer | 0.428942 |
| good example | 0.428021 |
| non-smoker | 0.407426 |
| care staff | 0.426607 |
| nicotine affect | 0.427281 |
| babysitters | 0.406286 |
| body | 0.411562 |
| smoker | 0.414092 |
| children | 0.431937 |
| harms | 0.407652 |
| sure caretakers | 0.428123 |
| secondhand smoke | 0.971613 |
| non-smokers | 0.43912 |
| heart disease‚ | 0.429635 |
| Fact | 0.410452 |
| short time | 0.429909 |
| somebody | 0.406088 |
| health problems | 0.428728 |
| smokefree restaurants | 0.432863 |
| lung infections | 0.428228 |
| smoking indoors | 0.445671 |
| main way smoking | 0.477206 |
| Breathing problems | 0.428866 |
|
| indoor public places | 0.450365 |
| babies | 0.424287 |
| smokers | 0.419121 |
| air | 0.417572 |
| life | 0.412446 |
| Breathing secondhand smoke | 0.5983 |
| infant death syndrome | 0.453829 |
| smoking | 0.508887 |
| National Cancer Institute | 0.448359 |
| heart attack‚ | 0.429618 |
| kids | 0.411336 |
| quiz | 0.411311 |
| cigarette | 0.405834 |
| coughing‚ extra phlegm‚ | 0.454984 |
| bronchitis | 0.405901 |
| people | 0.432125 |
| home | 0.416331 |
| nannies | 0.405803 |
| severe attacks | 0.428972 |
| best thing | 0.428251 |
| shortness | 0.406847 |
| ear infections | 0.428442 |
| low birth weight | 0.454001 |
| family | 0.425482 |
|
CLICK HERE |
| 15486 |
National Cancer Institute |
Html |
es |
Delirio |
¿Qué es delirio? Delirio es un estado mental confuse. Se explican las causas de delirio, formas de tratarlo y preguntas para hacer al doctor. |
| delirio hiperactivo | 0.974791 |
|
|
CLICK HERE |
| 15633 |
National Cancer Institute |
Html |
en |
Step 1: Application Development & Submission |
There are nine research grant application types, each with specific procedures. Learn more about developing, submitting, and tracking a cancer research grant application. |
| small project application | 0.562018 |
| grant application types | 0.615791 |
| Funding Opportunity Announcement | 0.657432 |
| grant applications | 0.709584 |
| institution business official | 0.474155 |
| Grants.gov Tracking Number | 0.523008 |
| ongoing extramural activity | 0.49934 |
| NIH’s Application | 0.521892 |
| Grants.gov Registration | 0.46434 |
| application requirements | 0.476818 |
| Administrative Supplement Request | 0.466071 |
| specific receipt date | 0.531978 |
| grant type | 0.487204 |
| specific IC program | 0.505666 |
| peer review processes | 0.498397 |
| prior approval | 0.560178 |
| well-defined scientific area | 0.49086 |
| eRA Commons | 0.962876 |
| receipt date | 0.604332 |
| Electronic grant applications | 0.606906 |
| NIH Guide | 0.481058 |
| program announcement | 0.579666 |
|
| NCI Grant Policies | 0.586226 |
| sam registration | 0.473955 |
| scientific peer review | 0.497797 |
| Small Business Innovation | 0.484684 |
| application status changes—the | 0.535723 |
| NCI Funding Opportunities | 0.538102 |
| NIH | 0.523095 |
| recent budget project | 0.476777 |
| Scientific Review Group | 0.50345 |
| NCI RFA | 0.467797 |
| application submission deadline | 0.550381 |
| grant support | 0.469498 |
| important application basics | 0.5838 |
| strong application | 0.469473 |
| application | 0.872468 |
| application cycles | 0.489855 |
| final assembled application | 0.53419 |
| additional prior approval | 0.492691 |
| grant application | 0.737304 |
| standing receipt date | 0.526741 |
| Small Business Technology | 0.489507 |
|
CLICK HERE |
| 16857 |
National Cancer Institute |
Html |
en |
Prior Approval Requests |
null |
| recipient institution | 0.428349 |
| current policies | 0.408224 |
| NoA | 0.327733 |
| NIH recipients | 0.49032 |
| enforcement action | 0.408587 |
| latitude | 0.326586 |
| prior approval requests | 0.721397 |
| specific prior approval | 0.686294 |
| grants management specialist | 0.645519 |
| certain degree | 0.434218 |
| copies | 0.318206 |
| prior approval authority | 0.69999 |
| terms | 0.318069 |
| prior approval | 0.984844 |
| unanticipated requirements | 0.40335 |
| total costs | 0.405045 |
| Questions | 0.317851 |
| makes certain budget | 0.539233 |
| NIH Grants Policy | 0.559485 |
| limits | 0.321806 |
| email | 0.319573 |
| recipient’s discretion | 0.470347 |
| cc | 0.322104 |
|
| termination | 0.321773 |
| Circumstances | 0.323427 |
| types | 0.321678 |
| cases | 0.320114 |
| subject line | 0.413724 |
| budget categories | 0.540205 |
| Statement | 0.318087 |
| GMO | 0.360575 |
| disallowance | 0.318052 |
| grants management officer | 0.531732 |
| proposed change | 0.416195 |
| agency authority | 0.407763 |
| NCI program director | 0.515619 |
| unauthorized officials | 0.411596 |
| PD/PI | 0.318695 |
| undertakes particular activities | 0.523 |
| expenditures | 0.324868 |
| response | 0.318742 |
| post-award changes | 0.427573 |
| grant number | 0.410914 |
| unanticipated needs | 0.427883 |
| responses | 0.319676 |
| risk | 0.318261 |
|
CLICK HERE |